Haixing Ju

Dr. Haixing Ju


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 April 2020 in Gastroenterology Report
Verified
Journal Article
Open access
PDF file
WJWu Jiang
Wu Jiang
QSQiao-Qi Sui
Qiao-Qi Sui
WLWen-Liang Li
Wen-Liang Li
CKChuan-Feng Ke
Chuan-Feng Ke
YLYi-Hong Ling
Yi-Hong Ling
PDPeirong Ding
Peirong Ding
Although universal testing for mismatch repair deficiency (dMMR) has been recommended to all colorectal cancer (CRC) patients, related evidence for the Chinese population is lacking. Here, we investigated the prevalence and clinicopathological features of dMMR patients in a large Chinese CRC cohort. We included 7,373 CRC patients treated at four Chinese medical centers between August 2010 and September 2016. Patients’ baseline characteristics and pathological features were recorded. The clinicopathological features were compared between patients with MLH1/PMS2 deficiency (dMLH1/PMS2) and MSH2/MSH6 deficiency (dMSH2/MSH6). Among the investigated patients, 654 (8.9%) were identified with dMMR CRCs and, of them, 401 (61.3%) were males, with a median age of 55 years (range, 22–87 years); 355 (54.3%) had stage II CRC based on American Joint Committee on Cancer 8th edition. The prevalence of the dMLH1/PMS2 group and the dMSH2/MSH6 group were 51.5% (337/654) and 25.1% (164/654), respectively. Compared with dMSH2/MSH6 patients, those with dMLH1/PMS2 were older (57 vs 52 years, P < 0.001), more likely to be female (45.7% vs 31.5%, P = 0.004), prone to having tumors located in the right-hand side of the colon (59.0% vs 47.6%, P = 0.015), and less likely to have a family history of tumors (29.7% vs 43.3%, P = 0.003). The prevalence of dMMR in Chinese CRC patients was low, especially in the dMLH1/PMS2 group. The clinicopathological features were different between dMMR subgroups.


16 June 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
ZZZhenyuan Zhou
Zhenyuan Zhou
XHXin Han
Xin Han
DSDiandian Sun
Diandian Sun
ZLZhiying Liang
Zhiying Liang
WWWei Wu
Wei Wu
HJHaixing Ju
Haixing Ju
Background: For patients with colorectal cancer liver metastases (CRLMs), it is important to stratify patients according to the risk of recurrence. This study aimed to validate the predictive value of some clinical, imaging, and pathology biomarkers and develop an operational prognostic model for patients with CRLMs with neoadjuvant chemotherapy (NACT) before the liver resection.Methods: Patients with CRLMs accompanied with primary lesion and liver metastases lesion resection were enrolled into this study. A nomogram based on independent risk factors was identified by Kaplan–Meier analysis and multivariate Cox proportional hazard analysis. The predictive ability was evaluated by receiver operating characteristic (ROC) curves and decision curve analysis (DCA). Calibration plot were also used to explore the consistency between prediction and reality.Results: A total of 118 patients were enrolled into the study. Multivariable Cox analysis found that histopathological growth patterns (HGPs) [Hazard Rate (HR) = 2.130], radiology response (stable disease vs. partial response, HR = 2.207; progressive disease vs. partial response, HR = 3.824), lymph node status (HR = 1.442), and age (HR = 0.576) were independent risk factors for disease-free survival (DFS) (p < 0.05). Corresponding nomogram was constructed on the basis of the above factors, demonstrating that scores ranging from 5 to 11 presented better prognosis than the scores of 0–4 (median DFS = 14.3 vs. 4.9 months, p < 0.0001). The area under ROC curves of the model for 1-, 2-, and 3-year DFS were 0.754, 0.705, and 0.666, respectively, and DCA confirmed that the risk model showed more clinical benefits than clinical risk score. Calibration plot for the probability of DFS at 1 or 3 years verified an optimal agreement between prediction and actual observation. In the course of our research, compared with pure NACT, a higher proportion of desmoplastic HGP (dHGP) was detected in patients treated with NACT plus cetuximab (p = 0.030), and the use of cetuximab was an independent factor for decreased replacement HGP (rHGP) and increased dHGP (p = 0.049).Conclusion: Our model is concise, comprehensive, and high efficient, which may contribute to better predicting the prognosis of patients with CRLMs with NACT before the liver resection. In addition, we observed an unbalanced distribution of HGPs as well.

1 April 2009
Verified
Journal Article
Closed access
HJHaixing Ju
Haixing Ju
NXNg Xu
Ng Xu
DLDechuan Li
Dechuan Li
GCGuiping Chen
Guiping Chen
GSGuoliang Shao
Guoliang Shao

1 January 2009
Verified
Journal Article
Closed access
YCYin-Bo Chen
Yin-Bo Chen
HJHaixing Ju
Haixing Ju
SZSu-Zhan Zhang
Su-Zhan Zhang
JPJia-Ping Peng
Jia-Ping Peng
DLDe-Chuan Li
De-Chuan Li

1 October 2012
Verified
Journal Article
Closed access
YLYong Liu
Yong Liu
GZGu Zhang
Gu Zhang
JQJun Qian
Jun Qian
YZYu-Ping Zhu
Yu-Ping Zhu
HJHaixing Ju
Haixing Ju
DLDe-Chuan Li
De-Chuan Li